Why Intellia Therapeutics Stock Jumped This Week
Shares of the gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) rose by 17.5% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. There are currently eight medications approved by the FDA to prevent and/or treat HAE attacks. NTLA-2002, however, could be the first genetic medicine for this indication (depending on its ongoing clinical trials).